v3.20.4
Collaborations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's receivable from Janssen $ 8,822 $ 5,428  
AbbVie's payable to Janssen $ 20,159 11,832  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Janssen Biotech, Inc | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 295 321 $ 326
AbbVie's receivable from Janssen 283 235  
AbbVie's payable to Janssen 562 455  
Janssen Biotech, Inc | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 2,012 1,803 1,372
Janssen Biotech, Inc | Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 1,009 844 622
Genentech, Inc. | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 533 320 141
AbbVie's share of development costs (included in R&D) 129 128 160
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 46 $ 41 $ 27